DBVT · DBV Technologies S.A. American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow DBVT by emailGet an email when DBVT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DBVT, unsubscribe in one click. Privacy
📣 What DBVT Says Is Next
second half of 2026 · “BLA submission for 1-3 year olds anticipated in the second half of 2026 under an Accelerated Approval Pathway Financial Highlights for the Full Year 2025 2025 Financial Highlights are presented under both U.S. GAAP and IFRS.”
Company press release, Mar 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full DBVT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DBVT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.